• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Derma Sciences sales jump 16 percent | Earnings roundup

Derma Sciences sales jump 16 percent | Earnings roundup

March 31, 2011 By MassDevice staff

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Derma Sciences sales jump 16 percent
Derma Sciences Inc. (NSDQ:DSCI) reported losses of $347,198, or 5 cents per diluted share, on sales of $15.3 million during the three months ended Dec. 31, 2010. That compares with profits $843, or less than 1 cent per diluted share, on sales of $13.6 million during the same period in 2009.

Full-year losses were $2.4 million, or 39 cents per share, on sales of $56.5 million. That compares with losses of $1.3 million, or 25 cents per share, on sales of $48.5 million in 2009.
Read more

Bacterin losses widen more than 340 percent
Bacterin International Holdings Inc. (NYSE Amex:BONE) reported losses of $5.5 million, or 15 cents per basic share, on sales of $5.3 million during the three months ended Dec. 31, 2010. That compares with losses of $1.6 million, or 6 cents per basic share, on sales of $2.2 million during the same period in 2009.

Full-year losses were $18.2 million, or 57 cents per share, on sales of $15.4 million. That compares with losses of $4.1 million, or 16 cents per share, on sales of $7.4 million in 2009.
Read more

Response Genetics losses halve
Response Genetics Inc. (NSDQ:RGDX) reported losses of $1.1 million, or 6 cents per basic share, on sales of $6.4 million during the three months ended Dec. 31. That compares with losses of $1.7 million, or 11 cents per diluted share, on sales of $3.4 during the same period in 2009.

Full-year losses were $4.7 million, or 26 cents per share, on sales of $21.3 million. That compares with losses of $9.3 million, or 70 cents per share, on sales of $9.1 million in 2009.
Read more

Nephros losses remain unchanged after small sales bump
Nephros Inc. (OTC:NEPHD) reported losses of $665,000, or 32 cents per diluted share, on sales of $517,000 during the three months ended Dec. 31, 2010. That compares with losses of $483,000, or 25 cents per diluted share, on sales of $792,000 during the same period in 2009.

Full-year losses were $1.9 million, or 93 cents per share, on sales of $2.9 million. That compares with losses of $2.0 million, or $1.06 per share, on sales of $2.7 million in 2009.
Read more

Guided Therapeutics losses ease after sales double
Guided Therapeutics Inc. (OTC:GTHP) reported losses of $280,000, or 1 cent per diluted share, on sales of $1.1 million during the three months ended Dec. 31, 2010. That compares with losses of $1.5 million, or 8 cents per diluted share, on sales of $550,000 during the same period in 2009.

Full-year losses were $4.5 million, or 12 cents per share, on sales of $3.4 million. That compares with losses of $6.4 million, or 38 cents per share, on sales of $1.6 million in 2009.
Read more

Elbit sales push company into the black
Elbit Imaging Ltd. (NSDQ:EMITF) reported profits of $19.5 million on sales of $111.9 million during the year ended Dec. 31, 2010. That compares with losses of $190.6 million on no revenue in 2009.
Read more

Spherix losses ease despite unchanged sales
Spherix Inc. (NSDQ:SPEX) reported losses of $7.7 million, or 43 cents per diluted share, on sales of $1.4 million during the year ended Dec. 31, 2010. That compares with losses of $9.1 million, or 62 cents per diluted share, on sales of $1.4 million in 2009.
Read more

NeurogesX losses double
NeurogesX Inc. (NSDQ:NGSX) reported losses of $12.4 million, or 69 cents per diluted share, on sales of $458,000 during the three months ended Dec. 31, 2010. That compares with losses $5.1 million, or 29 cents per diluted share, on no revenues during the same period in 2009.

Full-year losses were $44.5 million, or $2.51 cents per share, on sales of $688,000. That compares with losses of $21.9 million, or $1.24 per share, on no revenues in 2009.
Read more

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: Bacterin International Holdings Inc., Derma Sciences Inc., Elbit Imaging Ltd., Guided Therapeutics Inc., Nephros, NeurogesX Inc., Q4, Response Genetics Inc., Spherix Inc.

More recent news

  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year
  • Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy